NCT01567735View on ClinicalTrials.gov

A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients

PHASE3CompletedINTERVENTIONAL

Enrollment

107

Participants

Timeline

Start Date

March 27, 2012

Primary Completion Date

March 20, 2014

Study Completion Date

March 20, 2014

Conditions

Hepatitis C

Interventions

DRUG

TMC435

Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TMC435 capsule is taken once daily for 12 weeks.

Trial Locations (8)

Unknown

Antwerp

Brussels

Edegem

Clichy

Créteil

Lyon

Paris

Villejuif

All Listed Sponsors

lead

Janssen R&D Ireland

INDUSTRY

NCT01567735 - A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients | Biotech Hunter | Biotech Hunter